Ocuphire Pharma Investor Update

RM 28 MIRA Program Evaluating Nyxol for the Reversal of Mydriasis Efficient Clinical Programs have Positioned Ocuphire to Target NDA Filing in Late 2022 MIRA-1 2019 Phase 2b n=32 crossover Primary Endpoint Met ✓ Secondary Endpoints Met ✓ MIRA-2 2021 Phase 3 n=185 Primary Endpoint Met ✓ Secondary Endpoints Met ✓ MIRA-3 2022 Phase 3 n=368 Primary Endpoint Met ✓ Secondary Endpoints Met ✓ MIRA-4 2022 Pediatric Safety n=23 Fully Enrolled 3-11 years old RM NDA Filing 2022 NDA Submission Ocuphire PHARMA

View entire presentation